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The Hedgehog (Hh) proteins comprise a group of secreted proteins that regulate cell growth, differentiation and
survival. Inappropriate activation of the Hh signaling pathway has been implicated in the development of a variety
of cancers. Hedgehog pathway inhibitors are a relatively new class of therapeutic agents that act by targeting the
proteins involved in the regulation of Hh pathway (PTCH, SMO and Gli). Together, they serve as exciting new
prospects, with a bright future, both alone or as an adjuvant to the more traditional anti-cancer drugs.Letter
The Hedgehog (Hh) proteins comprise a group of
secreted proteins that regulate cell growth, differenti-
ation and survival [1]. They are involved in organogen-
esis, and have been shown to promote adult stem cell
proliferation [2,3]. Inappropriate activation of the Hh
signaling pathway has been implicated in the develop-
ment of several types of cancers including prostate, lung,
pancreas, breast, brain and skin [4-9].
Sonic Hedgehog (Shh) is the best studied ligand of Hh
pathway in vertebrates. In the absence of the ligand, the
Patched (PTCH) receptor inhibits Smoothened (SMO), a
downstream protein in the pathway. Binding of Shh to
PTCH alleviates this inhibition, thus regulating the ex-
pression of Gli transcription factors [10]. Loss-of-
function mutations of PTCH, gain-of-function mutations
of SMO and misexpression of the Gli2 and Gli3 have
been associated with tumor formation and maintenance
in animal models of medulloblastoma and basal cell car-
cinoma of the skin [11-14]. Other studies have pointed
towards Hedgehog signaling having an important role in
angiogenesis (by increasing angiopoietin-1 and angio-
poietin-2), metastasis (by increasing Snail expression)
and suppression of apoptosis (by increasing Cyclins and
anti-apoptotic factors and decreasing pro-apoptotic
genes such as Fas) [15-18].
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reproduction in any medium, provided the orinvolved in the regulation of Hh pathway. Cyclopamine
is the prototype inhibitor of the Shh pathway that inacti-
vates SMO by binding to its hepta-helical bundle [19]. It
is currently undergoing preclinical and clinical studies as
an anticancer agent in basal cell carcinoma, medullo-
blastoma and rhabdomyosarcoma [20,21]. Saridegib (IPI-
926), a synthetic analog of cyclopamine, has shown posi-
tive results in Phase I clinical trial of advanced solid
tumors [22]. Similarly, itraconazole, an antifungal drug,
has also been shown to suppress growth of medullo-
blastoma in mice allograft models [23]. This com-
pound acts as an SMO antagonist, in a manner
distinct from its anti-lanosterol activity in fungi (other
azole drugs have not been found to have this effect).
Other candidates for future trials include Novartis’
LDE-225, Millennium Pharmaceuticals' TAK-441, Exelixis/
Bristol-Myers Squibb's BMS-833923 (XL139) and Pfizer's
PF-04449913 [24,25].
Vismodegib (IPI-926; Erivedge: Genentech, South St
Francisco, CA, USA) has been recently approved by the
FDA for treatment of advanced basal cell carcinoma
[26]. However, like other drugs in the category, it also
has an adverse effect profile. Due to its mechanism of
action, it is contraindicated during pregnancy, as it is
teratogenic, embryotoxic and fetotoxic [27]. Other ad-
verse reactions include alopecia, muscle spasms, weight
loss, fatigue, GIT disturbances and arthralgias [27].
The approval of Vismodegib by the FDA can prove to
be the beginning of a new era in anti-cancer therapeu-
tics. Other drugs targeting the Hh pathway are likely to
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